RoACTEMRA (tocilizumab)

RoACTEMRA (tocilizumab, known as ACTEMRA outside of the EU) is the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody developed for the treatment of RA (rheumatoid arthritis) and is a novel approach to help tackle this debilitating disease. IL-6 has been identified as having a fundamental role in the inflammation process in RA.

RoACTEMRA, in combination with methotrexate (MTX), is indicated for the treatment of adult patients with moderate to severe RA who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. In these patients, RoACTEMRA can be given as monotherapy in cases of intolerance to methotrexate (MTX) or where continued treatment with MTX is inappropriate.